Basilea reported encouraging interim data for the derazantinib registrational Phase II trial in intrahepatic cholangiocarcinoma ("iCCA"), a few months earlier than we had anticipated. The overall response rate ("ORR") of 21% is in line with the efficacy observed in a previous Phase I/II trial and clinically relevant given the poor prognosis of the disease and the lack of 2nd line therapies, thus paving the way for a potential accelerated approval upon completion of the study in mid-2020E. The da ....
10 Jan 2019
Derazantinib interim data in line with expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Derazantinib interim data in line with expectations
Basilea Pharmaceutica AG (0QNA:LON) | 4,620 0 0.0% | Mkt Cap: 605.3m
- Published:
10 Jan 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
Basilea reported encouraging interim data for the derazantinib registrational Phase II trial in intrahepatic cholangiocarcinoma ("iCCA"), a few months earlier than we had anticipated. The overall response rate ("ORR") of 21% is in line with the efficacy observed in a previous Phase I/II trial and clinically relevant given the poor prognosis of the disease and the lack of 2nd line therapies, thus paving the way for a potential accelerated approval upon completion of the study in mid-2020E. The da ....